More common associations found between BRCA1 and BRCA2 mutations and cancer

December 05, 2006

BRCA1 and BRCA2 mutations may be more common in the general population than previously reported and may be associated with ovarian, breast, testicular, and pancreatic cancers, according to a study in the December 6 issue of the Journal of the National Cancer Institute.

Mutations in the BRCA1 and BRCA2 genes are known to lead to breast and ovarian cancer. However, the frequency of these mutations in the general population has not been well-characterized.

Harvey A. Risch, M.D., Ph.D., of the Yale University School of Medicine in New Haven, Conn., and colleagues looked for BRCA1 and BRCA2 mutations in 1,171 ovarian cancer patients from Ontario who were diagnosed between 1995 and 1999. They examined cancer outcomes in the patients' 8,680 first-degree relatives.

The authors found that 13.2% of the ovarian cancer patients had BRCA1 or BRCA2 mutations compared with 0.32% for BRCA1 mutations and 0.69% for BRCA2 mutations in the general Ontario population. BRCA1 mutations in the general Ontario population were associated with higher risk of ovarian, female breast, and testicular cancers. BRCA2 mutations in the general Ontario population were associated with higher risks of male and female breast, ovarian, and pancreatic cancer. They estimated that about 1% of people in the general Ontario population carried these mutations, which is much higher than had been previously thought.

"BRCA1 and BRCA2 mutations should be suspected in families with breast, ovarian, and various other cancers in male relatives as well as female," the authors write.

In an accompanying editorial, Kenneth Offit, M.D., of Memorial Sloan-Kettering Cancer Center, writes that the implications for doctors and patients remain unchanged. The prevalence of BRCA2 mutations associated with ovarian cancer "still warrants consideration of risk-reducing surgery, albeit at a somewhat older age than that recommended for BRCA1 mutation carriers. ...BRCA mutation status remains one of the strongest markers for risk of this disease, warranting increased surveillance with such modalities as magnetic resonance imaging, hormonal and other chemoprevention, and, in selected circumstances, preventive surgery."
-end-
Contact: Citations:Note: The Journal of the National Cancer Institute is published by Oxford University Press and is not affiliated with the National Cancer Institute. Attribution to the Journal of the National Cancer Institute is requested in all news coverage. Visit the Journal online at http://jncicancerspectrum.oxfordjournals.org/.

Journal of the National Cancer Institute

Related Ovarian Cancer Articles from Brightsurf:

Ovarian cancer cells cooperate to metastasize
In a study on human ovarian cancer cells in mice, Harvard Medical School researchers discovered a transient, cooperative interaction between cell subpopulations that allows otherwise nonmetastatic tumor cells to become aggressive and spread.

Photodynamic therapy used to treat ovarian cancer
Photodynamic therapy (PDT) is one of the most promising methods of treating localized tumors.

Studying the development of ovarian cancer with organoids
Researchers from the group of Hans Clevers at the Hubrecht Institute have modeled the development and progression of high-grade serous ovarian cancer in mini-versions, or organoids, of the female reproductive organs of the mouse.

New class of drugs could treat ovarian cancer
A team of researchers across the University of Manchester have shown that a new class of drugs are able to stop ovarian cancer cells growing.

How to catch ovarian cancer earlier
Ovarian cancer is often diagnosed too late for effective treatment.

New compound could help treat ovarian cancer
Scientists from the University of Sheffield have discovered a compound that could be more effective in treating certain cancers than standard chemotherapy.

Epigenetic markers of ovarian cancer
Insilico Medicine and its collaborators from Johns Hopkins and Insilico Medicine, used an integrated approach by coupling identification of genome-wide expression patterns in multiple cohorts of primary ovarian cancer samples and normal ovarian surface epithelium with innovative computational analysis of gene expression data, leading to the discovery of novel cancer-specific epigenetically silenced genes.

Ovarian cancer statistics, 2018
A new report from the American Cancer Society provides an overview of ovarian cancer occurrence and mortality data.

Ovarian cancer drug shows promise in pancreatic cancer patients with BRCA mutation
A targeted therapy that has shown its power in fighting ovarian cancer in women including those with BRCA1 and BRCA2 mutations may also help patients with aggressive pancreatic cancer who harbor these mutations and have few or no other treatment options.

TGen-led study finds potent anti-cancer drug effect in rare ovarian cancer
An anti-cancer drug used to fight leukemia shows promise against a rare and aggressive type of ovarian cancer -- small cell carcinoma of the ovary hypercalcemic type (SCCOHT) -- which strikes young women and girls, according to a study led by the TGen.

Read More: Ovarian Cancer News and Ovarian Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.